-
1.47 billion yuan! Hanson Pharma has introduced Pumis Bio EGFR/cMet for Greater China
Hanson Pharma will acquire exclusive rights to develop and commercialize PM1080 in Greater China.
2022-11-17 10:38 -
Harbourbiomed set up a subsidiary Nona biological
Nona Biology creatively opens the industry-leading Harbour Mice® platform, and eliminates platform barriers with a more flexible business model as a ...
2022-11-17 10:38 -
International, Junshi Biology is serious! pd1 filed for listing in Europe
The sea is just around the corner.
2022-11-17 10:38 -
Novo Nordisk Shanghai and ShanghaiPharmaceutical Holdings sign a contract to make another breakthrou...
(hereinafter referred to as "NovoNordisk Shanghai") and Shanghai Pharmaceutical Holdings Limited(hereinafter referred to as "Shanghai Pharmaceutical H...
2022-11-15 14:26 -
Global Vaccine Market Rises to the TopAgain
The global vaccine market is a blue oceanin 2021. New coronavirus vaccine leads the market
2022-11-15 14:25 -
Multinational medical companies use theExpo platform to quickly 'integrate' into China
At the 5th China Import Expo in Shanghai,two achievements of Boston Scientific's "localization strategy" werepresented for the first time
2022-11-15 14:24 -
Hainan to promote drug import facilitation
Recently, the thirty-eighth meeting of theStanding Committee of the Sixth People's Congress of Hainan Province consideredand adopted the "Hainan Free ...
2022-11-15 14:22 -
Enable the 'export of EU APIcertification documents' and 'pharmaceutical export salescertificate' el...
Since December 1, 2022, the official launchof the "export of EU API certification documents" and"pharmaceutical export sales certificate" electronic p...
2022-11-15 14:21 -
Semaglutide once a week for the treatment of adolescent obesity Phase III results appear in the New ...
On November 2, the New England Journal of Medicine published an article entitled "Once a week Semaglutide treatment of adolescent obesity".
2022-11-08 09:59 -
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
Taking paxlovid during COVID-19 infection significantly reduces the risk of COVID-19 sequelae.
2022-11-07 16:46
Hot News
- 关于进一步规范化学品信息发布、... Jan 27, 2026
- BASF’s 2025 Report Card—“Th... Jan 27, 2026
- Invista Reshuffles Global Nylo... Jan 28, 2026
- 5%–10% Is Just the Surface: B... Jan 15, 2026
- “Europe’s Chemical Industry ... Feb 02, 2026
Related Products
Related Producers
